Drug Makers Press For U.S. Trade Sanctions On Thailand
This article was originally published in PharmAsia News
Executive Summary
Drug makers are about to press the U.S. Trade Representative to impose sanctions on Thailand for refusing to drop its compulsory license moves to drive down the price of certain medicines. The director general of Thailand's Intellectual Property Department said the Pharmaceutical Research and Manufacturers of America, which met in Singapore recently, had threatened a strong lobbying effort to get the U.S. policy change. The sanction process envisioned would reduce Thailand from the Priority Watch List where it is now to Priority Foreign Country that makes a nation subject to trade sanctions. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.